We are live on ! Find out more
DA

DCF Advisers Portfolio holdings

AUM $375M
1-Year Est. Return 72.65%
This Fund
S&P 500
This Quarter Est. Return
+5.2%
1 Year Est. Return
+72.65%
3 Year Est. Return
+156.29%
5 Year Est. Return
+218.72%
10 Year Est. Return
–
AUM
$250M
AUM Growth
+$56M
Cap. Flow
+$44.7M
Cap. Flow %
17.87%
Top 10 Hldgs %
51.39%
Holding
108
New
15
Increased
21
Reduced
34
Closed
11

Top Buys

Rank Stock Value
1
AMZN icon
Amazon
AMZN
+$3.19M
2
MU icon
Micron Technology
MU
+$1.73M
3
C icon
Citigroup
C
+$1.45M
4
URNM icon
Sprott Uranium Miners ETF
URNM
+$1.1M
5
AMGN icon
Amgen
AMGN
+$818K

Top Sells

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$2.95M
2
AAPL icon
Apple
AAPL
+$2.23M
3
RVNC
Revance Therapeutics, Inc.
RVNC
+$1.15M
4
GLD icon
SPDR Gold Trust
GLD
+$916K
5
BHVN icon
Biohaven
BHVN
+$805K

Sector Composition

Rank Sector Weight
1 Healthcare 26.92%
2 Technology 16.18%
3 Communication Services 7.16%
4 Consumer Discretionary 6.33%
5 Financials 3.42%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VOO icon
1
PUT
Vanguard S&P 500 ETF
VOO
$979B
$47.3M 18.9%
+89,600
New +$45.5M
MU icon
2
Micron Technology
MU
$930B
$18.3M 7.32%
176,500
+16,500
+10% +$1.73M
GOOG icon
3
Alphabet (Google) Class C
GOOG
$4.36T
$11.6M 4.65%
69,650
-2,000
-3% -$339K
ARGX icon
4
argenx
ARGX
$53.4B
$10.8M 4.33%
20,000
– –
REGN icon
5
Regeneron Pharmaceuticals
REGN
$78.5B
$8.15M 3.26%
7,750
-2,650
-25% -$2.95M
ITCI
6
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$7.35M 2.94%
100,507
– –
AMZN icon
7
Amazon
AMZN
$2.92T
$6.43M 2.57%
34,500
+17,500
+103% +$3.19M
AMD icon
8
Advanced Micro Devices
AMD
$776B
$6.24M 2.49%
38,000
– –
LLY icon
9
Eli Lilly
LLY
$1.02T
$6.2M 2.48%
7,000
– –
ABBV icon
10
AbbVie
ABBV
$443B
$6.12M 2.45%
31,000
-800
-3% -$149K
ORCL icon
11
Oracle
ORCL
$374B
$5.96M 2.38%
35,000
-1,750
-5% -$253K
IAU icon
12
iShares Gold Trust
IAU
$62.9B
$4.97M 1.99%
100,000
– –
ET icon
13
Energy Transfer Partners
ET
$70.1B
$4.96M 1.98%
309,250
– –
BAC icon
14
Bank of America
BAC
$435B
$4.74M 1.9%
119,500
-5,850
-5% -$234K
BABA icon
15
Alibaba
BABA
$293B
$4.59M 1.83%
43,250
-1,550
-3% -$127K
GLD icon
16
SPDR Gold Trust
GLD
$131B
$4.38M 1.75%
18,000
-4,000
-18% -$916K
SLV icon
17
iShares Silver Trust
SLV
$28B
$4.25M 1.7%
149,500
+2,900
+2% +$77.9K
XNCR icon
18
Xencor
XNCR
$1.5B
$4.21M 1.68%
209,479
+500
+0.2% +$9.39K
BIDU icon
19
Baidu
BIDU
$37.7B
$3.74M 1.49%
35,500
+5,500
+18% +$486K
AMGN icon
20
Amgen
AMGN
$208B
$3.54M 1.42%
11,000
+2,500
+29% +$818K
INCY icon
21
Incyte
INCY
$24.2B
$3.19M 1.27%
48,250
-3,250
-6% -$207K
TPB icon
22
Turning Point Brands
TPB
$1.45B
$3.1M 1.24%
71,800
-2,000
-3% -$76.4K
GDX icon
23
VanEck Gold Miners ETF
GDX
$22.7B
$2.99M 1.19%
75,000
+15,500
+26% +$587K
ZBH icon
24
Zimmer Biomet
ZBH
$18.2B
$2.52M 1.01%
23,319
+1,600
+7% +$175K
AOD
25
abrdn Total Dynamic Dividend Fund
AOD
$1.11B
$2.38M 0.95%
261,500
– –
1
2 3 4 5

Similar funds

JIC
JRM Investment Counsel Omaha, Nebraska $375M AUM 13.43% 1-Year Est. Return
CIM
CIM Investment Management Pittsburgh, Pennsylvania $375M AUM 32.03% 1-Year Est. Return
AIM
Access Investment Management Atlanta, Georgia $376M AUM 17.2% 1-Year Est. Return
MWM
McMill Wealth Management Norfolk, Nebraska $376M AUM 14.46% 1-Year Est. Return
RCP
RIT Capital Partners London, United Kingdom $374M AUM 25.18% 1-Year Est. Return
HPM
Helix Partners Management New York $374M AUM 136.73% 1-Year Est. Return
CAG
Compass Advisory Group Melville, New York $374M AUM 14.59% 1-Year Est. Return
LWMNY
Landmark Wealth Management (New York) Melville, New York $373M AUM 12.01% 1-Year Est. Return

DCF Advisers's Q3 2024 Portfolio in Review

As of Q3 2024, DCF Advisers held 108 positions worth $250M, up 29% from $194M the previous quarter. Its ten largest holdings account for 51% of the portfolio.

DCF Advisers deployed $44.7M of net new capital in Q3 2024, opening 15 new positions and adding to 21 existing holdings. Its largest new stake was NewAmsterdam Pharma: 34,000 shares worth $564K.

By sector, the portfolio is most concentrated in Healthcare at 27% of assets, down from 34% a quarter earlier, followed by Technology and Communication Services.

On the sell side, the largest reduction was Regeneron Pharmaceuticals, an estimated $2.95M trimmed.

  • DCF Advisers's largest Q3 2024 buy was NewAmsterdam Pharma: 34,000 shares worth $564K.
  • DCF Advisers added most to Amazon in Q3 2024, an estimated $3.19M increase.
  • DCF Advisers's biggest Q3 2024 reduction was Regeneron Pharmaceuticals, cutting an estimated $2.95M.
  • DCF Advisers fully exited Snowflake in Q3 2024, selling an estimated $439K.
  • DCF Advisers's ten largest holdings make up 51% of its $250M portfolio in Q3 2024.
  • DCF Advisers opened 15 new positions and closed 11 in Q3 2024.
  • DCF Advisers's portfolio value rose 29% quarter-over-quarter to $250M.

Based on DCF Advisers's 13F filing for Q3 2024, filed 13 Nov 2024.